<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1705">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04568863</url>
  </required_header>
  <id_info>
    <org_study_id>PHM-2020-001</org_study_id>
    <nct_id>NCT04568863</nct_id>
  </id_info>
  <brief_title>Efficacy of Intravenous Melatonin on Mortality in Adult Patients Admitted to the Intensive Care Unit With COVID-19</brief_title>
  <acronym>MELCOVID</acronym>
  <official_title>A Phase II, Single-center, Double-blind, Randomized Placebo-controlled Trial to Explore the Efficacy and Safety of Intravenous Melatonin in Patients With COVID-19 Admitted to the Intensive Care Unit (MelCOVID Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmamel S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Investigación Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pharmamel S.L.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is an urgent need to evaluate effective treatments for COVID-19 patients. Melatonin has
      significant anti-inflammatory and antioxidant properties and it lacks of side-effects. This
      randomized controlled trial seeks to evaluate the efficacy of intravenous melatonin in
      reducing mortality in Covid-19 patients in the ICUs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ICU COVID-19 patients show high risk of death mainly due to sepsis and respiratory
      disfunction. Prevention of these critical conditions is mandatory to reduce mortality and to
      improve patient's outcome.

      Melatonin is an endogenous hormone involved not only in circadian rhythm control, but also in
      the cell protection due to its outstanding anti-inflammatory and antioxidative effects. High
      doses of melatonin have shown high efficacy against bacterial (sepsis) and viral infections.
      Melatonin is a safe product that consistently has shown lack of side-effects when it is
      administered to humans.

      SARS-CoV 2 infection may yield severe forms of the disease that require the patients
      admission to the ICU. These patients may develop an excessive inflammatory response and a
      burst of free radicals, constituting the major cause of death in these subjects.

      Our hypothesis is that high doses of melatonin intravenously administered to COVID-19 ICU
      patients might reach enough blood levels able to prevent/counteract the developing of sepsis
      and the production of free radicals, reducing mortality and hospital stay.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>phase II, single-center, double-blind, randomized placebo-controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>one month</time_frame>
    <description>Mortality in each study group represented in frequency and time-to-event at day 28 after randomization</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>COVID-19</condition>
  <condition>SARS-CoV 2</condition>
  <condition>Coronavirus Infection</condition>
  <arm_group>
    <arm_group_label>Melatonin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(12 patients): 7 days of 5 mg per Kg of actual body weight per day of intravenous melatonin every 6 hours. Maximum daily dose 500 mg per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>(6 patients): 7 days of 5 mg per Kg of actual body weight per day of intravenous identically-looking placebo every 6 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin intravenous</intervention_name>
    <description>7 days of 5 mg per Kg of actual body weight per day of intravenous melatonin every 6 hours. Maximum daily dose 500 mg per day.</description>
    <arm_group_label>Melatonin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo intravenous</intervention_name>
    <description>7 days of 5 mg per Kg of actual body weight per day of intravenous identically-looking placebo every 6 hours.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient, family member or legal guardian has provided written Informed Consent.

          -  Age ε 18 years.

          -  Confirmed SARS-CoV-2 infection with compatible symptoms AND a positive RT-PCR.

          -  Admission to the ICU with acute hypoxemic respiratory failure attributed to SARS-CoV-2
             infection.

          -  ICU length of stay of less than 7 days prior to randomization with or without MV and
             without signs of improvement in respiratory failure (MURRAY score at randomization
             greater or equal to the MURRAY score at ICU admission).

        Exclusion Criteria:

          -  Participant in a different COVID-19 study in which the study drug is under clinical
             development and hasn't been previously authorized for commercialization.

          -  Liver enzymes &gt; 5 times the upper normal range.

          -  Chronic kidney disease with GFR &lt; 30 mL/min/1.73 m2 (stage 4 or greater) or need for
             hemodialysis.

          -  Pregnancy. A pregnancy test will be performed on every woman younger than 55 years of
             age prior to inclusion.

          -  Terminal surgical or medical illness.

          -  Autoimmune disease.

          -  Any patient condition that can prevent the study procedures to be carried out at the
             treating physician's judgement.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Germaine Escames, PhD</last_name>
    <phone>+34950241000</phone>
    <phone_ext>20363</phone_ext>
    <email>gescames@ugr.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Germaine Escames, PhD</last_name>
      <phone>+34958241000</phone>
      <phone_ext>20363</phone_ext>
      <email>gescames@ugr.es</email>
    </contact>
    <contact_backup>
      <last_name>Darío Acuña-Castroviejo, PhD</last_name>
      <phone>+34958241000</phone>
      <phone_ext>20169</phone_ext>
      <email>dacuna@ugr.es</email>
    </contact_backup>
    <investigator>
      <last_name>Juan C Figueira, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pedro C de la Oliva, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cristina Arévalo Martín, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudio Gutiérrez Mavarez, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andoni García Muñoz, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alberto Borovia, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Irene García García, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miguel Rodríguez Rubio, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>José M Añón, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>José R Arribas, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julio García Rodríguez, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Darío Acuña-Castroviejo, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Germaine Escames, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Rodríguez-Rubio M, Figueira JC, Acuña-Castroviejo D, Borobia AM, Escames G, de la Oliva P. A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial. Trials. 2020 Aug 5;21(1):699. doi: 10.1186/s13063-020-04632-4.</citation>
    <PMID>32758298</PMID>
  </reference>
  <reference>
    <citation>Acuña-Castroviejo D, Escames G, Figueira JC, de la Oliva P, Borobia AM, Acuña-Fernández C. Clinical trial to test the efficacy of melatonin in COVID-19. J Pineal Res. 2020 Oct;69(3):e12683. doi: 10.1111/jpi.12683. Epub 2020 Aug 8.</citation>
    <PMID>32770854</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 28, 2020</study_first_submitted>
  <study_first_submitted_qc>September 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2020</study_first_posted>
  <last_update_submitted>September 28, 2020</last_update_submitted>
  <last_update_submitted_qc>September 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Melatonin intravenous</keyword>
  <keyword>Placebo intravenous</keyword>
  <keyword>ICU patients</keyword>
  <keyword>COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

